EZH2 and melanoma: Solid tumors often exhibit EZH2 overexpression, as reported in various cancer types, with adverse outcomes, including prostate cancer, breast cancer, endometrial cancer, colorectal cancer, melanoma, cholangiocarcinoma, and ovarian cancer.